|
1
|
Kubota K, Watanabe K, Kunitoh H, Kunitoh
H, Noda K, Ichinose Y, Katakami K, Sugiura T, Kawahara M Yokoyama
A, et al: Phase III randomized trial of docetaxel plus cisplatin
versus vindesine plus cisplatin in patients with stage IV
non-small-cell lung cancer: The Japanese Taxotere Lung Cancer Study
Group. J Clin Oncol. 22:254–261. 2004.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Segawa Y, Kiura K, Takigawa N, Kamei H,
Harita S, Hiraki S, Watanabe Y, Sugimoto K, Shibayama T, Yonei T,
et al: Phase III trial comparing docetaxel and cisplatin
combination chemotherapy with mitomycin, vindesine, and cisplatin
combination chemotherapy with concurrent thoracic radiotherapy in
locally advanced non-small-cell lung cancer: OLCSG 0007. J Clin
Oncol. 28:3299–3306. 2010.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Shukuya T, Yamanaka T, Seto T, Daga H,
Goto K, Saka H, Sugawara S, Takahashi T, Yokota S, Kaneda H, et al:
Nedaplatin plus docetaxel versus cisplatin plus docetaxel for
advanced or relapsed squamous cell carcinoma of the lung
(WJOG5208L): A randomised, open-label, phase 3 trial. Lancet Oncol.
16:1630–1638. 2015.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Fossella FV, DeVore R, Kerr RN, Crawford
J, Natale RR, Dunphy F, Kalman L, Miller V, Lee JS, Moore M, et al:
Randomized phase III trial of docetaxel versus vinorelbine or
ifosfamide in patients with advanced non-small-cell lung cancer
previously treated with platinum-containing chemotherapy regimens.
The TAX 320 non-small cell lung cancer study group. J Clin Oncol.
18:2354–2362. 2000.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Boggaram V: Thyroid transcription factor-1
(TTF-1/Nkx2.1/TITF1) gene regulation in the lung. Clin Sci (Lond).
116:27–35. 2009.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Gronberg BH, Lund-Iversen M, Strom EH,
Brustugun OT and Scott H: Associations between TS, TTF-1, FR-α,
FPGS, and overall survival in patients with advanced non-small-cell
lung cancer receiving pemetrexed plus carboplatin or gemcitabine
plus carboplatin as first-line chemotherapy. J Thorac Oncol.
8:1255–1264. 2013.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Takeuchi A, Oguri T, Yamashita Y, Sone K,
Fukuda S, Takakuwa O, Uemura T, Maeno K, Fukumitsu K, Kanemitsu Y,
et al: TTF-1 expression predicts the merit of additional
antiangiogenic treatment in non-squamous non-small cell lung
cancer. Anticancer Res. 38:5489–5495. 2018.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Chung KP, Huang YT, Chang YL, Yu CJ, Yang
CH, Chang YC, Shih JY and Yang PC: Clinical significance of thyroid
transcription factor-1 in advanced lung adenocarcinoma under
epidermal growth factor receptor tyrosine kinase inhibitor
treatment. Chest. 141:420–428. 2012.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Pelosi G, Fabbri A, Bianchi F, Maisonneuve
P, Rossi G, Barbareschi M, Graziano P, Cavazza A, Rekhtman N,
Pastorino U, et al: DeltaNp63 (p40) and thyroid transcription
factor-1 immunoreactivity on small biopsies or cellblocks for
typing non-small cell lung cancer: A novel two-hit,
sparing-material approach. J Thorac Oncol. 7:281–290.
2012.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Kanda Y: Investigation of the freely
available easy-to-use software ‘EZR’ for medical statistics. Bone
Marrow Transplant. 48:452–458. 2013.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Reck M, Rodriguez-Abreu D, Robinson AG,
Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe
S, et al: Pembrolizumab versus chemotherapy for PD-L1-positive
non-small-cell lung cancer. N Engl J Med. 375:1823–1833.
2016.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Gandhi L, Rodriguez-Abreu D, Gadgeel S,
Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ,
Powell SF, et al: Pembrolizumab plus chemotherapy in metastatic
non-small-cell lung cancer. N Engl J Med. 378:2078–2092.
2018.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Paz-Ares L, Luft A, Vicente D, Tafreshi A,
Gümüş M, Mazières J, Hermes B, Çay Şenler F, Csőszi T, Fülöp A, et
al: Pembrolizumab plus chemotherapy for squamous non-small-cell
lung cancer. N Engl J Med. 379:2040–2051. 2018.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Socinski MA, Jotte RM, Cappuzzo F, Orlandi
F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D, Moro-Sibilot D,
Thomas CA, Barlesi F, et al: Atezolizumab for first-line treatment
of metastatic nonsquamous NSCLC. N Engl J Med. 378:2288–2301.
2018.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Hanna N, Shepherd FA, Fossella FV, Pereira
JR, De Marinis F, von Pawel J, Gatzemeier U, Tsao TC, Pless M,
Muller T, et al: Randomized phase III trial of pemetrexed versus
docetaxel in patients with non-small-cell lung cancer previously
treated with chemotherapy. J Clin Oncol. 22:1589–1597.
2004.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Burkhart CA, Kavallaris M and Band Horwitz
S: The role of beta-tubulin isotypes in resistance to antimitotic
drugs. Biochim Biophys Acta. 1471:O1–O9. 2001.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Seve P, Mackey J, Isaac S, Trédan O,
Souquet PJ, Pérol M, Lai R, Voloch A and Dumontet C: Class III
beta-tubulin expression in tumor cells predicts response and
outcome in patients with non-small cell lung cancer receiving
paclitaxel. Mol Cancer Ther. 4:2001–2007. 2005.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Vasile E, Tibaldi C, Leon GL, D'Incecco A
and Giovannetti E: Cytochrome P450 1B1 (CYP1B1) polymorphisms are
associated with clinical outcome of docetaxel in non-small cell
lung cancer (NSCLC) patients. J Cancer Res Clin Oncol.
141:1189–1194. 2015.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Powrozek T, Mlak R, Krawczyk P, Bartoń S,
Biernacka B, Małecka-Massalska T and Milanowski J: Retrospective
analysis of second-line chemotherapy outcomes with paclitaxel or
docetaxel in correlation with STMN1 polymorphism in advanced
non-small cell lung cancer patients. Clin Transl Oncol. 18:33–39.
2016.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Szczyrek M, Mlak R, Krawczyk P,
Wojas-Krawczyk K, Powrózek T, Szudy-Szczyrek A, Zwolak A, Daniluk J
and Milanowski J: Polymorphisms of Genes encoding multidrug
resistance proteins as a predictive factor for second-line
docetaxel therapy in advanced non-small cell lung cancer. Pathol
Oncol Res. 23:607–614. 2017.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Sone K, Oguri T, Ito K, Kitamura Y, Inoue
Y, Takeuchi A, Fukuda S, Takakuwa O, Maeno K, Asano T, et al:
Predictive role of CYFRA21-1 and CEA for subsequent docetaxel in
non-small cell lung cancer patients. Anticancer Res. 37:5125–5131.
2017.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Tanaka H, Yanagisawa K, Shinjo K, Taguchi
A, Maeno K, Tomida S, Shimada Y, Osada H, Kosaka T, Matsubara H, et
al: Lineage-specific dependency of lung adenocarcinomas on the lung
development regulator TTF-1. Cancer Res. 67:6007–6011.
2007.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Wu J, Chu PG, Jiang Z and Lau SK: Napsin A
expression in primary mucin-producing adenocarcinomas of the lung:
An immunohistochemical study. Am J Clin Pathol. 139:160–166.
2013.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Sumiyoshi S, Yoshizawa A, Sonobe M,
Kobayashi M, Sato M, Fujimoto M, Tsuruyama T, Date H and Haga H:
Non-terminal respiratory unit type lung adenocarcinoma has three
distinct subtypes and is associated with poor prognosis. Lung
Cancer. 84:281–288. 2014.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Takeuchi T, Tomida S, Yatabe Y, Kosaka T,
Osada H, Yanagisawa K, Mitsudomi T and Takahashi T: Expression
profile-defined classification of lung adenocarcinoma shows close
relationship with underlying major genetic changes and
clinicopathologic behaviors. J Clin Oncol. 24:1679–1688.
2006.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Yatabe Y, Kosaka T, Takahashi T and
Mitsudomi T: EGFR mutation is specific for terminal respiratory
unit type adenocarcinoma. Am J Surg Pathol. 29:633–639.
2005.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Lisberg A, Cummings A, Goldman JW,
Bornazyan K, Reese N, Wang T, Coluzzi P, Ledezma B, Mendenhall M,
Hunt J, et al: A phase II study of pembrolizumab in EGFR-Mutant,
PD-L1+, tyrosine kinase inhibitor naive patients with advanced
NSCLC. J Thorac Oncol. 13:1138–1145. 2018.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Herbst RS, Baas P, Kim DW, Felip E,
Pérez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, et al:
Pembrolizumab versus docetaxel for previously treated,
PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010):
A randomised controlled trial. Lancet. 387:1540–1550.
2016.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Borghaei H, Paz-Ares L, Horn L, Spigel DR,
Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al:
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell
lung cancer. N Engl J Med. 373:1627–1639. 2015.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Garon EB, Ciuleanu TE, Arrieta O, Prabhash
K, Syrigos KN, Goksel T, Park K, Gorbunova V, Kowalyszyn RD, Pikiel
J, et al: Ramucirumab plus docetaxel versus placebo plus docetaxel
for second-line treatment of stage IV non-small-cell lung cancer
after disease progression on platinum-based therapy (REVEL): A
multicentre, double-blind, randomised phase 3 trial. Lancet.
384:665–673. 2014.PubMed/NCBI View Article : Google Scholar
|
